Related Experiment Videos
Triaryl methane derivatives as antiproliferative agents.
Raed A Al-Qawasmeh1, Yoon Lee, Ming Yu Cao
1Lorus Therapeutics Inc., 2Meridian Road, M9W 4Z7, Toronto, ON, Canada.
Bioorganic & Medicinal Chemistry Letters
|December 31, 2003
Summary
Clotrimazole (CLT) inhibits tumor cell growth by arresting the cell cycle. Researchers developed CLT analogues to reduce liver toxicity while maintaining anti-cancer efficacy, with promising results.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Clotrimazole (CLT) is a synthetic anti-fungal imidazole derivative with demonstrated anti-tumor properties.
- CLT inhibits tumor cell proliferation and angiogenesis, crucial processes in cancer development.
- The imidazole moiety in CLT is linked to potential hepatotoxicity.
Purpose of the Study:
- To investigate the mechanism of CLT-induced tumor cell growth inhibition.
- To develop novel CLT analogues lacking the imidazole moiety to mitigate hepatotoxicity.
- To retain the anti-cancer efficacy of CLT in the new derivatives.
Main Methods:
- Flow cytometry was employed to analyze cell cycle progression.
- Tumor cell lines were treated with CLT and its analogues.
- In vitro antiproliferative activity assays were performed.
Main Results:
- CLT treatment resulted in cell cycle arrest at the G(0)-G(1) phase, specifically inhibiting the G(1)-S phase transition.
- A series of CLT analogues were synthesized, successfully removing the imidazole group.
- Most analogues exhibited significant in vitro antiproliferative activity at submicromolar to micromolar concentrations.
Conclusions:
- CLT effectively inhibits tumor cell proliferation by inducing G(0)-G(1) cell cycle arrest.
- Novel CLT analogues demonstrate potential as less hepatotoxic anti-cancer agents.
- The developed analogues retain significant anti-proliferative efficacy, warranting further investigation.